BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News

Cardiovascular Disorder (misc) News Articles

Get Our Industry eNewsletter FREE email:    
 Top Breaking News
Servier Release: European Medicines Agency Recommends Measures To Reduce Risk Of Heart Problems With Corlentor/Procoralan (Ivabradine)     11/21/2014
Sanofi And Regeneron's Alirocumab Ph3 Trials Met Primary Efficacy Endpoint     11/20/2014
Merck & Co.'s Vytorin Proves Effective; IMPROVE-IT Trial Achieves Primary Endpoint     11/19/2014
Best Value In Biotech? Actavis, Says UBS     11/17/2014
ZS Pharma Presents Positive Results From HARMONIZE (ZS004), A Second Phase 3 Clinical Trial Of ZS-9 In Patients With Hyperkalemia, At The American Heart Association Scientific Meeting And Announces Simultaneous Publication Of Results In JAMA     11/17/2014
Alnylam Pharmaceuticals Reports Positive Initial Phase 2 Data With Revusiran     11/14/2014
Boehringer Ingelheim Corporation Passes on Anthera, Inc.'s CV Antibody Option     11/13/2014
AstraZeneca PLC To Test Whether It Can Undo Effects Of Its Own Heart Drug Brilinta     11/13/2014
Cardiome Pharma Corp. Touts Positive Data From Phase 3 BRINAVESS® Trial     11/7/2014
FDA Panel Backs Daiichi Sankyo, Inc.'s New A-Fib Drug Savaysa     10/31/2014
Bay Area Startup MyoKardia Forges $200 Million Heart Disease Pact With Sanofi (France)     9/17/2014
Wall Street Overreacting To Amarin Denial: Citigroup Analyst     9/12/2014
Amgen, Servier Heart Drug Runs Into Safety Concerns In Major Clinical Study     9/4/2014
Resverlogix Corporation's RVX-208 Leads To A 77 Percent Relative Risk Reduction Of Major Heart Events     9/2/2014
AstraZeneca PLC Says U.S. Authorities End Probe Into Clinical Trial Of Star Heart Drug Brilinta     8/19/2014
 Featured Stories
Emotional Stress Affects Women's Heart More, Emory University Study     11/17/2014
Long Term Shift Work Linked To Impaired Brain Function, Occupational & Environmental Medicine Reveals     11/5/2014
Mental Health Disorders Double Heart Disease, Stroke Risk, Centre For Addiction And Mental Health Study     10/28/2014
Drinking Two Sodas A Day Can Age You 4 Years, University of California, San Francisco (UCSF) Study     10/21/2014
How Omega-6 Fatty Acids Lower Bad Cholesterol, Innsbruck Medical University Study     10/20/2014
Americans Living Longer As Fewer Die From Heart Disease, Cancer, CDC Reveals     10/13/2014
How To Predict Who Will Suffer The Most From Stress, Concordia University Study     10/2/2014
Healthy Fats Help Diseased Heart Muscle Process, Use Fuel, University of Illinois Study     10/1/2014
Cardiorespiratory Fitness Slashes High Blood Pressure Hikes In Men, University of South Carolina Study     9/17/2014
Inflammation May Be Key To Diabetes/Heart Disease Link, Universidad Autónoma de Madrid Study     9/16/2014
Short Walking Breaks Reverse Harmful Effects Of Prolonged Sitting, Indiana University Study     9/10/2014
Wine Only Protects The Heart When You Exercise, Palacky University Study     9/9/2014
Drinking Tea, Not Coffee, Could Help You Live Longer, European Society of Cardiology Reveals     9/3/2014
Energy Drinks Cause Heart Problems, European Society of Cardiology Reveals     9/2/2014
Instant Noodles Can Lead To An Early Death, Baylor University Medical Center Study Reveals     8/19/2014
 More News
Milestone Pharmaceuticals Announces Positive Phase 1 Data For MSP-2017; Supports Advancement Into Phase 2 In PSVT Patients     11/24/2014
Kaiser Permanente Release: Digoxin Associated With Higher Risk of Death and Hospitalization in Adults With Atrial Fibrillation and No Heart Failure     11/21/2014
NeoStem, Inc. Announces Initial Positive Data From Phase 2 Preserve AMI Clinical Trial     11/18/2014
Capricor Therapeutics, Inc. Announces Favorable ALLSTAR Phase I Safety Results     11/18/2014
Boehringer Ingelheim Pharmaceuticals, Inc. Release: Interim Data Reinforce Safety and Effectiveness of Pradaxa (dabigatran etexilate mesylate) versus Warfarin in Routine Care of Patients with Non-valvular Atrial Fibrillation     11/18/2014
CSL Release: CSL112 Found To Elevate Cholesterol Efflux In Patients With Coronary Artery Disease And Mechanism For Rapid Cholesterol Efflux Capacity Demonstrated     11/18/2014
Abbott Laboratories (ABT) Release: People With Chronic Obstructive Pulmonary Disease (COPD) Who Received Nutrition Treatment In The Hospital Had Better Health Outcomes     11/17/2014
AstraZeneca PLC (AZN) Announces Initiation of Development Program For BRILINTA (ticagrelor) Reversal Agent     11/13/2014
Broad Institute And Massachusetts Institute of Technology (MIT) Defective NPC1L1 Gene Found To Protect Against Heart Disease     11/13/2014
CSL Limited (CMXHF.PK) Launches AEGIS-I, A Phase 2b Clinical Study Of CSL112, A Novel Apolipoprotein A-I Infusion Therapy Designed To Rapidly Remove Cholesterol From Arteries And Stabilize Plaque     11/12/2014
Matinas BioPharma Commences Dosing In First Human Trial Of Lead Product Candidate MAT9001     11/12/2014
Juventas Therapeutics, Inc. Phase 2 Clinical Study Results To Be Presented At 2014 American Heart Association Scientific Sessions     11/12/2014
GlaxoSmithKline (GSK) Survey Points to Rise of COPD in U.S.     11/11/2014
Alnylam Pharmaceuticals (ALNY) Completes Phase 2 Enrollment And Initiates Open-Label Extension (OLE) Study With Revusiran (ALN-TTRsc), An Investigational Rnai Therapeutic Targeting Transthyretin (TTR) For The Treatment Of TTR Cardiac Amyloidosis     11/5/2014
3D Virtual Implantation Demonstrated That 19-Year-Old Female Could Be Successfully Bridged To Transplant With The SynCardia Systems, Inc. Total Artificial Heart     11/4/2014